Acasti Pharma, Inc./$GRCE
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Acasti Pharma, Inc.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Ticker
$GRCE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
6
ISIN
US00439U1043
Website
GRCE Metrics
BasicAdvanced
$43M
-
-$0.79
0.91
-
Price and volume
Market cap
$43M
Beta
0.91
52-week high
$4.69
52-week low
$1.75
Average daily volume
43K
Financial strength
Current ratio
11.768
Quick ratio
11.533
Profitability
EBITDA (TTM)
-16.67
Effective tax rate (TTM)
25.06%
Management effectiveness
Return on assets (TTM)
-14.35%
Return on equity (TTM)
-14.91%
Valuation
Price to book
0.64
Price to tangible book (TTM)
2.48
Price to free cash flow (TTM)
-2.538
Free cash flow yield (TTM)
-39.39%
Free cash flow per share (TTM)
-123.30%
Growth
Earnings per share change (TTM)
-41.31%
3-year earnings per share growth (CAGR)
-20.89%
GRCE News
AllArticlesVideos
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
GlobeNewsWire·1 week ago
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
GlobeNewsWire·2 weeks ago
Grace Therapeutics to Participate in the 2025 BIO International Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Acasti Pharma, Inc. stock?
Acasti Pharma, Inc. (GRCE) has a market cap of $43M as of July 04, 2025.
What is the P/E ratio for Acasti Pharma, Inc. stock?
The price to earnings (P/E) ratio for Acasti Pharma, Inc. (GRCE) stock is 0 as of July 04, 2025.
Does Acasti Pharma, Inc. stock pay dividends?
No, Acasti Pharma, Inc. (GRCE) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Acasti Pharma, Inc. dividend payment date?
Acasti Pharma, Inc. (GRCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Acasti Pharma, Inc.?
Acasti Pharma, Inc. (GRCE) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.